Author(s):
Avantika Dhadwal, Ankita Rana, Sakshi Sharma, Gaurav Bhardwaj
Email(s):
ranaavantika270@gmail.com
DOI:
10.52711/2321-5836.2024.00051 
Address:
Avantika Dhadwal*, Ankita Rana, Sakshi Sharma, Gaurav Bhardwaj
Department of Pharmaceutics, Himachal Institute of Pharmaceutical Education and Research, Nadaun, Himachal Pradesh, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2024
ABSTRACT:
Middle Eastern respiratory syndromes (MERS-CoV) are a novel coronavirus discovered in Saudi Arabia in 2012, with several outbreaks connected to the Arabian Peninsula. The virus has a high fatality rate and no effective antiviral medication or vaccination. It is known to spread mainly among bats and mammals, with close contact being the most likely way to spread the disease. MERS-CoV, SARS-CoV, and SARS-CoV-2 are all initially transmitted via mammals to humans. Medications like Lopinavir and ritonavir are used to treat COVID-19 caused by SARS-CoV-2. Lopinavir inhibits the HIV-1 protease enzyme, promoting the formation of immature virus particles. Acyclovir is used to treat acute herpetic keratitis, varicella zoster, viral labialis, and herpes labialis, while Ribavirin is used to treat hemorrhagic fever caused by viruses and hepatitis C. Chloroquine, a synthetic guanosine nucleoside, was removed from FDA authorization for emergency therapy for COVID-19 in June 2020. It inhibits heme to hemozoin transformation in malarial trophozoites, destroying the parasite when harmful heme levels in Plasmodium species grow. Chloroquine is used to avoid and cure malaria, treats extra intestinal amebiasis, and in some hospitalized individuals for COVID-19 coronavirus treatment. To ensure safety, visitors should wash their hands before and after touching animals and avoid handling dromedary camels, consuming uncooked meat, or consuming camel milk or urine.
Cite this article:
Avantika Dhadwal, Ankita Rana, Sakshi Sharma, Gaurav Bhardwaj. A Review on MERS-CoV, The Coronavirus Linked to Middle Eastern Respiratory illness. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(4):297-0. doi: 10.52711/2321-5836.2024.00051
Cite(Electronic):
Avantika Dhadwal, Ankita Rana, Sakshi Sharma, Gaurav Bhardwaj. A Review on MERS-CoV, The Coronavirus Linked to Middle Eastern Respiratory illness. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(4):297-0. doi: 10.52711/2321-5836.2024.00051 Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-4-7
REFERENCES:
1. Zaki AM, Boheemena S, Bestebroer TIM, Osterhaus A, Fouchier R. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367: 1814–20. doi:10.1056/NEJMoa1211721.
2. Command and Control Center (CCC) Statistics – April 2016.Ministry of Health (MOH) – Kingdom of Saudi Arabia. http://www.moh.gov.sa/en/CCC/ PressReleases/Pages/default.aspx. Accessed 15 Apr 2016.
3. Tyrel DA, Bynoe ML. Cultivation of a novel type of common cold virus in organ culture. Br Med J. 1965; 1(5448): 1467–70
4. Boheemena S, Graafa M, Lauberb C, Bestebroera TM, Raja S, Zaki AM, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio. 3(6): doi: 10.1128/mBio.00473-12.
5. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015; 28: 465–522. doi:10.1128/CMR.00102-14.
6. A. M. Zaki, S. van Boheemen, T. M. Bestebroer, A. D. Osterhaus, R. A. Fouchier, N. Engl. J. Med. 2012; 367: 1814 – 1820.
7. A. Bermingham et al., Euro Surveill. 2012; 17: 20290.
8. World Health Organization, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (2015); www.who.int/emergencies/ mers-cov/en/.
9. Hemida MG, Elmoslemany A, Al-Hizab F, Alnaeem A, Almathen F, Faye B, Chu DK, Perera RA, Peiris M. Dromedary camels and the transmission of Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Transbound Emerg Dis. 2017; 64(2): 344–353
10. Adney DR, Bielefeldt-Ohmann H, Hartwig AE, Bowen RA. Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in alpacas. Emerging Infect Dis. 2016; 22(6): 1031–1037.
11. Adney DR, Letko M, Ragan IK, Scott D, van Doremalen N, Bowen RA, Munster VJ. Bactrian camels shed large quantities of Middle East respiratory syndrome coronavirus (MERS-CoV) after experimental infection. Emerg Microbes Infect. 2019; 8(1): 717–723.
12. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014; 370(26): 2499–2505.
13. Azhar EI, Hashem AM, El-Kafrawy SA, Sohrab SS, Aburizaiza AS, Farraj SA, Hassan AM, Al-Saeed MS, Jamjoom GA, Madani TA. Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient. MBio. 2014; 5(4): e01450–e01414.
14. De Benedictis P, Marciano S, Scaravelli D, Priori P, Zecchin B, Capua I, et al. Al-pha and lineage C betaCoV infections in Italian bats. Virus Genes. 2014; 48: 366–71. doi:10.1007/s11262-013-1008-x.
15. Wacharapluesadee S, Sintunawa C, Kaewpom T, Khongnomnan K, Olival KJ, Epstein JH, et al. Group C betacorona-virus in bat guano fertilizer, Thailand. Emerg Infect Dis. 2013; 19: 1349–51. doi:10.3201/eid1908.130119.
16. Annan A, Baldwin HJ, Corman VM, Klose SM, Owusu M, Nkrumah EE, et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis. 2013; 19: 456. doi:10.3201/eid1903.121503.
17. Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL. MERS: Emergence of a novel human coronavirus. Curr Opin Virol 2014; 5: 58–62. doi: 10.1016/j.coviro.2014.01.010
18. World Health Organization. Consensus document on the epidemiology ofsevere acute respiratory syndrome (SARS). 2003. Available: http://www.who.int/csr/sars/en/WHOconsensus.pdf. Accessed 29 June 2014.
19. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, et al. Genomic characterization of a newly discovered coronavirus associated withacute respiratory distress syndrome in humans. MBio. 2012; 3: e00473–12.doi:10.1128/mBio.00473-12.
20. World Health Organization (2014) Global Alert and Response: Middle East respiratory syndrome coronavirus (MERS-CoV) – update, 07 May 2014.Available: http://www.who.int/csr/don/ 2014_05_07_mers_yemen/en/. Ac-cessed 30 Aug 2014.
21. Reusken C, Farag E, Jonges M, Godeke G, El-Sayed A, et al. Middle east respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising anti-bodies in milk collected according to local customs from dromedary camels, Qatar. April 2014. Euro Surveill 19: p20829ii. Available: http:// www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20829. Accessed 6 November 2014.
22. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, et al. Hospital outbreak of middle east respiratory syndrome coronavirus. N Engl J Med. 2013; 369: 407–416. doi:10.1056/ NEJMoa1306742
23. Breban R, Riou J, Fontanet A. Interhuman transmissibility of middle east respiratory syndrome coronavirus: Estimation of pandemic risk. Lancet. 2013; 382: 694–699. doi:10.1016/S0140-6736(13)61492-0
24. Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL MERS: Emergence of a novel human coronavirus. Curr Opin Virol. 2014; 5: 58-62.
25. Mustafa, S., Balkhy, H., and Gabere, M. N. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review. Journal of Infection and Public Health. 2018; 11(1): 9-17. doi: 10.1016/j.jiph.2017.08.009.
26. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med. 2012 Jul; 2(7): a006924. doi: 10.1101/cshperspect. a006924
27. FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral use
28. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr; 33(4): 307-20. doi: 10.1016/j.ijantimicag.2008.10.010. Epub 2008 Dec 23.
29. King DH. History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol. 1988 Jan; 18(1 Pt 2): 176-9. doi: 10.1016/s0190-9622(88)70022-5.
30. O'Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar; 37(3): 233-309.
31. Miller WH, Miller RL. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol. 1982 Dec 1; 31(23): 3879-84. doi: 10.1016/0006-2952(82)90305-7.
32. Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008 Jun; 23(6): 844-55. doi: 10.1111/j.1440-1746.2008.05398. x.
33. Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y). 2007 Mar; 3(3): 218-25.
34. FDA. Emergency use Authorization for Hydroxychloroquine and Chloroquine Revoked
35. Coronado LM, Nadovich CT, Spadafora C. Malarial hemozoin: from target to tool. Biochim Biophys Acta. 2014 Jun; 1840(6): 2032-41. doi: 10.1016/j.bbagen.2014.02.009. Epub 2014 Feb 17.
36. Chou AC, Fitch CD. Heme polymerase: modulation by chloroquine treatment of a rodent malaria. Life Sci. 1992;51(26):2073-8. doi: 10.1016/0024-3205(92)90158-l
37. Slater AF, Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature. 1992 Jan 9; 355(6356): 167-9. doi: 10.1038/355167a0.
38. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996 Oct; 31(4): 257-74. doi: 10.2165/00003088-199631040-00003.
39. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020 Mar; 30(3): 269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
40. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22; 2: 69. doi: 10.1186/1743-422X-2-69.
41. Nature Biotechnology. Coronavirus puts drug repurposing on the fast track.